Literature DB >> 30322507

Distinct attentional function profiles in older adults receiving cancer chemotherapy.

Inger Utne1, Borghild Løyland1, Ellen Karine Grov1, Hege Lund Rasmussen1, Ann Helen Torstveit1, Bruce A Cooper2, Judy Mastick2, Melissa Mazor2, Melisa Wong3, Steven M Paul2, Yvette P Conley4, Thierry Jahan3, Christine Ritchie3, Jon D Levine3, Christine Miaskowski5.   

Abstract

PURPOSE: While attentional function is an extremely important patient outcome for older adults, research on changes in function in this group is extremely limited. The purposes of this study were to: identify subgroups of older patients (i.e., latent growth classes) based on changes in their level of self-reported attentional function; determine which demographic and clinical characteristics were associated with subgroup membership; and determine if these subgroups differed on quality of life (QOL) outcomes.
METHODS: Older oncology outpatients (n = 365) who were assessed for changes in attention and working memory using the Attentional Function Index a total of six times over two cycles of chemotherapy (CTX). QOL was assessed using the Medical Outcomes Study-Short Form 12 and the QOL-Patient Version Scale. Latent profile analysis (LPA) was used to identify subgroups of older adults with distinct attentional function profiles.
RESULTS: Three distinct attentional functional profiles were identified (i.e., low, moderate, and high attentional function). Compared to the high class, older adults in the low and moderate attentional function classes had lower functional status scores, a worse comorbidity profile and were more likely to be diagnosed with depression. In addition, QOL scores followed an expected pattern (low class < moderate class < high attentional function class).
CONCLUSIONS: Three distinct attentional function profiles were identified among a relatively large sample of older adults undergoing CTX. The phenotypic characteristics associated with membership in the low and moderate latent classes can be used by clinicians to identify high risk patients.
Copyright © 2018 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Attentional function; Chemotherapy; Cognitive function; Latent profile analysis; Older adults

Mesh:

Year:  2018        PMID: 30322507      PMCID: PMC6193264          DOI: 10.1016/j.ejon.2018.08.006

Source DB:  PubMed          Journal:  Eur J Oncol Nurs        ISSN: 1462-3889            Impact factor:   2.398


  62 in total

1.  Pretreatment symptom distress in women newly diagnosed with breast cancer.

Authors:  B Cimprich
Journal:  Cancer Nurs       Date:  1999-06       Impact factor: 2.592

2.  The Attentional Function Index--a self-report cognitive measure.

Authors:  Bernadine Cimprich; Moira Visovatti; David L Ronis
Journal:  Psychooncology       Date:  2011-02       Impact factor: 3.894

Review 3.  Executive functioning impairment in women treated with chemotherapy for breast cancer: a systematic review.

Authors:  Christie Yao; Lori J Bernstein; Jill B Rich
Journal:  Breast Cancer Res Treat       Date:  2017-07-13       Impact factor: 4.872

Review 4.  Cognitive Effects of Chemotherapy and Cancer-Related Treatments in Older Adults.

Authors:  Jennifer N Vega; Julie Dumas; Paul A Newhouse
Journal:  Am J Geriatr Psychiatry       Date:  2017-04-06       Impact factor: 4.105

Review 5.  Use of comprehensive geriatric assessment in older cancer patients: recommendations from the task force on CGA of the International Society of Geriatric Oncology (SIOG).

Authors:  Martine Extermann; Matti Aapro; Roberto Bernabei; Harvey Jay Cohen; Jean-Pierre Droz; Stuart Lichtman; Vincent Mor; Silvio Monfardini; Lazzaro Repetto; Liv Sørbye; Eva Topinkova
Journal:  Crit Rev Oncol Hematol       Date:  2005-09       Impact factor: 6.312

6.  Cognitive function of older patients receiving adjuvant chemotherapy for breast cancer: a pilot prospective longitudinal study.

Authors:  Arti Hurria; Carol Rosen; Clifford Hudis; Enid Zuckerman; Katherine S Panageas; Mark S Lachs; Matthew Witmer; Wilfred G van Gorp; Monica Fornier; Gabriella D'Andrea; Mark Moasser; Chau Dang; Catherine Van Poznak; Anju Hurria; Jimmie Holland
Journal:  J Am Geriatr Soc       Date:  2006-06       Impact factor: 5.562

Review 7.  Prevalence, mechanisms, and management of cancer-related cognitive impairment.

Authors:  Michelle C Janelsins; Shelli R Kesler; Tim A Ahles; Gary R Morrow
Journal:  Int Rev Psychiatry       Date:  2014-02

8.  Cognitive Dysfunction and Its Relationship to Quality of Life in Breast Cancer Survivors.

Authors:  Diane Von Ah; Kathleen M Russell; Anna Maria Storniolo; Janet S Carpenter
Journal:  Oncol Nurs Forum       Date:  2009-05-01       Impact factor: 2.172

Review 9.  Impact of Cancer and Its Treatments on Cognitive Function: Advances in Research From the Paris International Cognition and Cancer Task Force Symposium and Update Since 2012.

Authors:  Florence Joly; Bénédicte Giffard; Olivier Rigal; Michiel B De Ruiter; Brent J Small; Martine Dubois; Johan LeFel; Sanne B Schagen; Tim A Ahles; Jeffrey S Wefel; Janette L Vardy; Véronique Pancré; Marie Lange; Hélène Castel
Journal:  J Pain Symptom Manage       Date:  2015-09-05       Impact factor: 3.612

10.  Identification of candidate categories of the International Classification of Functioning Disability and Health (ICF) for a Generic ICF Core Set based on regression modelling.

Authors:  Alarcos Cieza; Szilvia Geyh; Somnath Chatterji; Nenad Kostanjsek; Bedirhan T Ustün; Gerold Stucki
Journal:  BMC Med Res Methodol       Date:  2006-07-27       Impact factor: 4.615

View more
  7 in total

1.  Symptom clusters in outpatients with cancer using different dimensions of the symptom experience.

Authors:  Carolyn S Harris; Kord M Kober; Bruce Cooper; Yvette P Conley; Anand A Dhruva; Marilyn J Hammer; Steven Paul; Jon D Levine; Christine A Miaskowski
Journal:  Support Care Cancer       Date:  2022-05-11       Impact factor: 3.603

2.  Pre-Surgery Demographic, Clinical, and Symptom Characteristics Associated with Different Self-Reported Cognitive Processes in Patients with Breast Cancer.

Authors:  Yu-Yin Allemann-Su; Marcus Vetter; Helen Koechlin; Steven M Paul; Bruce A Cooper; Kate Oppegaard; Michelle Melisko; Jon D Levine; Yvette Conley; Christine Miaskowski; Maria C Katapodi
Journal:  Cancers (Basel)       Date:  2022-07-05       Impact factor: 6.575

3.  Distinct Worst Pain Profiles in Oncology Outpatients Undergoing Chemotherapy.

Authors:  Joosun Shin; Kate Oppegaard; Alejandra Calvo-Schimmel; Carolyn Harris; Bruce A Cooper; Steven M Paul; Yvette P Conley; Marilyn J Hammer; Frances Cartwright; Kord M Kober; Jon D Levine; Christine Miaskowski
Journal:  Cancer Nurs       Date:  2022-04-12       Impact factor: 2.760

4.  Co-occurrence of decrements in physical and cognitive function is common in older oncology patients receiving chemotherapy.

Authors:  Inger Utne; Bruce A Cooper; Christine Ritchie; Melisa Wong; Laura B Dunn; Borghild Loyland; Ellen Karine Grov; Marilyn J Hammer; Steven M Paul; Jon D Levine; Yvette P Conley; Kord M Kober; Christine Miaskowski
Journal:  Eur J Oncol Nurs       Date:  2020-08-03       Impact factor: 2.398

Review 5.  Four decades of chemotherapy-induced cognitive dysfunction: comprehensive review of clinical, animal and in vitro studies, and insights of key initiating events.

Authors:  Ana Dias-Carvalho; Mariana Ferreira; Rita Ferreira; Maria de Lourdes Bastos; Susana Isabel Sá; João Paulo Capela; Félix Carvalho; Vera Marisa Costa
Journal:  Arch Toxicol       Date:  2021-11-02       Impact factor: 5.153

Review 6.  Age-related differences in self-report and objective measures of cognitive function in older patients prior to chemotherapy.

Authors:  Inger Utne; Borghild Løyland; Ellen Karine Grov; Hege Lund Rasmussen; Ann Helen Torstveit; Steven M Paul; Christine Ritchie; Kristina Lindemann; Ingvild Vistad; Claudia Rodríguez-Aranda; Christine Miaskowski
Journal:  Nurs Open       Date:  2021-12-08

7.  Co-occuring symptoms in older oncology patients with distinct attentional function profiles.

Authors:  Inger Utne; Borghild Løyland; Ellen Karine Grov; Steven Paul; Melisa L Wong; Yvette P Conley; Bruce A Cooper; Jon D Levine; Christine Miaskowski
Journal:  Eur J Oncol Nurs       Date:  2019-07-02       Impact factor: 2.398

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.